Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × INDUSTRY × Hormone Refractory Prostate Cancer × Clear all

Phase

Status

Completed 6 Terminated 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 403 Carcinoma, Non-Small-Cell Lung 368 Breast Neoplasms 285 Neoplasm Metastasis 194 Colorectal Neoplasms 174 Melanoma 169 Leukemia, Myeloid, Acute 163 Multiple Myeloma 145 Recurrence 138 Prostatic Neoplasms 136 Ovarian Neoplasms 136 Lymphoma, Non-Hodgkin 125 Lung Neoplasms 107 Lymphoma 102 Pancreatic Neoplasms 100 Leukemia, Lymphocytic, Chronic, B-Cell 93 Squamous Cell Carcinoma of Head and Neck 89 Carcinoma, Renal Cell 88 Leukemia 75 Lymphoma, Large B-Cell, Diffuse 74 Carcinoma, Hepatocellular 73 Stomach Neoplasms 72 Lymphoma, Follicular 69 Head and Neck Neoplasms 66 Triple Negative Breast Neoplasms 64 Urinary Bladder Neoplasms 60 Myelodysplastic Syndromes 58 Glioblastoma 57 Small Cell Lung Carcinoma 50 Precursor Cell Lymphoblastic Leukemia-Lymphoma 43

Interventions

Mycobacterium w vaccine 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00525408 2012-03-12

HRPC

Cadila Pharnmaceuticals

Phase 2 Terminated

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡